Orchestra Biomed Holdings Inc
OBIO2.690USD
+0.250+10.25%
取引時間 （ET）15分遅れの株価
USD0.000前場取引 (ET)
103.06M時価総額
損失額直近12ヶ月PER
四半期
四半期+年間
四半期
年間
YOY
空白行を非表示にする
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
総売上高
40.00%868.00K
-3.44%253.00K
135.56%987.00K
-14.97%778.00K
-46.74%620.00K
-76.25%262.00K
-63.97%419.00K
128.18%915.00K
34.41%1.16M
144.97%1.10M
-12.75%1.16M
141.00%401.00K
-34.19%866.00K
---2.45M
--1.33M
---978.00K
--1.32M
収益
40.00%868.00K
-3.44%253.00K
135.56%987.00K
-14.97%778.00K
-46.74%620.00K
-76.25%262.00K
-63.97%419.00K
128.18%915.00K
34.41%1.16M
144.97%1.10M
-12.75%1.16M
141.00%401.00K
-34.19%866.00K
---2.45M
--1.33M
---978.00K
--1.32M
売上原価
29.41%44.00K
23.40%58.00K
65.85%68.00K
-18.52%44.00K
-22.73%34.00K
-11.32%47.00K
-26.79%41.00K
575.00%54.00K
4.76%44.00K
-8.62%53.00K
27.27%56.00K
-87.10%8.00K
20.00%42.00K
--58.00K
--44.00K
--62.00K
--35.00K
営業費用
31.55%19.79M
32.86%16.93M
15.97%17.33M
27.15%17.64M
18.36%15.04M
16.58%12.74M
33.06%14.94M
72.63%13.87M
112.03%12.71M
100.42%10.93M
96.33%11.23M
74.45%8.04M
14.45%5.99M
--5.45M
--5.72M
--4.61M
--5.24M
研究 & 開発費
47.96%13.48M
28.90%10.97M
35.49%11.60M
30.91%11.13M
10.39%9.11M
12.83%8.51M
45.08%8.56M
72.95%8.50M
137.59%8.25M
113.62%7.54M
61.22%5.90M
86.35%4.91M
13.42%3.47M
--3.53M
--3.66M
--2.64M
--3.06M
減価償却費、減耗費および償却費
12.16%83.00K
16.67%84.00K
7.04%76.00K
1.37%74.00K
4.23%74.00K
2.86%72.00K
31.48%71.00K
46.00%73.00K
47.92%71.00K
45.83%70.00K
17.39%54.00K
13.64%50.00K
11.63%48.00K
--48.00K
--46.00K
--44.00K
--43.00K
営業利益
-31.19%-18.92M
-33.62%-16.68M
-12.52%-16.34M
-30.13%-16.86M
-24.93%-14.42M
-26.99%-12.48M
-44.27%-14.52M
-69.71%-12.96M
-125.14%-11.54M
-24.29%-9.83M
-129.47%-10.07M
-36.71%-7.63M
-30.78%-5.13M
---7.91M
---4.39M
---5.58M
---3.92M
営業外受取（支払）利息純額
特別利益（損失）
100.00%0.00
100.00%0.00
-100.00%0.00
25.81%-23.00K
83.93%-45.00K
-269.57%-1.45M
205.40%293.00K
-193.94%-31.00K
23.29%-280.00K
-529.67%-391.00K
59.48%-278.00K
111.91%33.00K
-162.50%-365.00K
--91.00K
---686.00K
---277.00K
--584.00K
その他営業外収益（費用）
100.00%0.00
--0.00
--0.00
--0.00
---11.00K
----
----
----
----
----
----
----
----
----
----
----
----
税引前利益
-39.31%-18.75M
-26.03%-16.16M
-15.85%-15.43M
-32.66%-15.98M
-23.06%-13.46M
-31.47%-12.82M
-29.51%-13.32M
-53.51%-12.05M
-90.96%-10.94M
-20.89%-9.75M
-95.59%-10.28M
-27.49%-7.85M
-61.97%-5.73M
---8.06M
---5.26M
---6.16M
---3.54M
税引後利益
-39.31%-18.75M
-26.03%-16.16M
-15.85%-15.43M
-32.66%-15.98M
-23.06%-13.46M
-31.47%-12.82M
-29.51%-13.32M
-53.51%-12.05M
-90.96%-10.94M
-20.89%-9.75M
-95.59%-10.28M
-27.49%-7.85M
-61.97%-5.73M
---8.06M
---5.26M
---6.16M
---3.54M
継続事業による純利益
-39.31%-18.75M
-26.03%-16.16M
-15.85%-15.43M
-32.66%-15.98M
-23.06%-13.46M
-31.47%-12.82M
-29.51%-13.32M
-53.51%-12.05M
-90.96%-10.94M
-20.89%-9.75M
-95.59%-10.28M
-27.49%-7.85M
-61.97%-5.73M
---8.06M
---5.26M
---6.16M
---3.54M
親会社株主に帰属する当期純利益
-39.31%-18.75M
-26.03%-16.16M
-15.85%-15.43M
-32.66%-15.98M
-23.06%-13.46M
-31.47%-12.82M
-29.51%-13.32M
-53.51%-12.05M
-90.96%-10.94M
-20.89%-9.75M
-95.59%-10.28M
-27.49%-7.85M
-61.97%-5.73M
---8.06M
---5.26M
---6.16M
---3.54M
優先株配当金
----
----
----
----
----
----
----
----
----
--0.00
--0.00
----
----
--0.00
--0.00
----
----
普通株主に帰属する純利益
-39.31%-18.75M
-26.03%-16.16M
-15.85%-15.43M
-32.66%-15.98M
-23.06%-13.46M
-31.47%-12.82M
-29.51%-13.32M
-53.51%-12.05M
-90.96%-10.94M
-20.89%-9.75M
-95.59%-10.28M
-27.49%-7.85M
-61.97%-5.73M
---8.06M
---5.26M
---6.16M
---3.54M
基本的1株当たり利益
-30.35%-0.49
-16.36%-0.42
-8.52%-0.41
-28.26%-0.45
4.92%-0.38
-18.34%-0.36
-16.24%-0.38
-40.29%-0.35
-118.51%-0.40
-20.89%-0.31
-95.59%-0.33
-27.49%-0.25
-61.97%-0.18
---0.25
---0.17
---0.19
---0.11
希薄化後1株当たり利益
-30.35%-0.49
-16.36%-0.42
-8.52%-0.41
-28.26%-0.45
4.92%-0.38
-18.34%-0.36
-16.24%-0.38
-40.29%-0.35
-118.51%-0.40
-20.89%-0.31
-95.59%-0.33
-27.49%-0.25
-61.97%-0.18
---0.25
---0.17
---0.19
---0.11
1株当たり配当金
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
通貨単位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
監査意見
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
